WoundReference improves clinical decisions
 Choose the role that best describes you
Motley TA, Caporusso JM, Lange DL, Eichelkraut RA, Cargill DI, Dickerson JE Jr, et al.
Advances in wound care. Date of publication 2018 Oct 1;volume 7(10):339-348.
1. Adv Wound Care (New Rochelle). 2018 Oct 1;7(10):339-348. doi: 10.1089/wound.2018.0784. Epub 2018 Oct 11. Clinical Outcomes for Diabetic Foot Ulcers Treated with Clostridial Collagenase Ointment or with a Product Containing Silver. Motley TA(1), Caporusso JM(2), Lange DL(3), Eichelkraut RA(3), Cargill DI(3), Dickerson JE Jr(4). Author information: (1)Department of Orthopedics, John Peter Smith Hospital and Acclaim Physician Group, Fort Worth, Texas. (2)Complete Family Footcare, McAllen, Texas. (3)Smith & Nephew, Fort Worth, Texas. (4)Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, Texas. Objective: To compare outcomes of diabetic foot ulcers (DFUs) treated with clostridial collagenase ointment (CCO) or silver-containing products, both in combination with sharp debridement as needed. Approach: One hundred two subjects with qualifying DFUs were randomized to daily treatment with either CCO or a silver-containing product for 6 weeks followed by a 4 -week follow-up period. The primary outcome was the mean percent reduction in DFU area. A secondary outcome was the incidence of ulcer infections between groups. Results: At the end of treatment, the mean percent reduction in area from baseline of DFUs treated with CCO was 62% (p < 0.0001) and with silver was 40% (p < 0.0001). The difference between groups-22%-was not statistically significant (p = 0.071). Among ulcers closed by the end of treatment, the mean time to closure was 31.1 ± 9.0 days versus 37.1 ± 7.7 days, respectively (not statistically significant). There was a numerically greater incidence of target ulcer infections in the silver group (11, 21.6%) than in the CCO group (5, 9.8%; p = 0.208). No clinically relevant safety signals were identified in either group. Innovation: CCO treatment can progress a wound toward closure. Ulcer infection prophylaxis may not be sacrificed when treating DFU with CCO in lieu of silver-containing products. Conclusion: Both CCO and silver-containing products promote significant reduction in DFU area over 6 weeks of treatment with no clinically relevant safety concerns. Mean percent reduction in lesion area was numerically (22%) but not significantly greater with CCO compared to silver, as was time to ulcer closure, with an incidence of ulcer infection at least as low as for silver-containing products. DOI: 10.1089/wound.2018.0784 PMCID: PMC6203225 PMID: 30374419
Appears in following Topics:
Diabetic Foot Ulcer - Treatment